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preferred because of severe neurological complications which occur in 
15-25%. 
In malignant mesothelioma, persistent resistant pain has been consid-
ered for percutaneous cordotomy, ie destruction of the contralateral 
spinothalamic tract in the neck. In 5 reports of 302 patients, pain relief 
was seen in 65%, respiratory depression in 0-4%, retention 6-10%, mir-
ror image pain 7-55%, and hemiparesis 0.4-9%. The opioid dose can be 
reduced thereby. A skilled team is essential. 
Adverse Events
Patients must be aware of these. Common errors are failure to prescribe 
early anti-emetics and bulk and stimulant laxatives when opioids are 
begun; to overlook the cholinergic side effects of tricyclics; the failure 
to decrease opioid doses in renal impairment; and the failure to use 
adequate opioids for fear of irrecoverable respiratory depression.
Prevention
Meticulous attention to analgesic management both intra and post 
operatively may reduce the incidence of post thoracotomy pain and 
accelerate recovery. Earlier palliative spine irradiation may postpone 
neurological problems and troublesome incident pain. 
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Although we have entered the era of targeted therapy in lung cancer, 
the back bone of initial treatment for most patients with either non-
small cell (NSCLC) or small cell lung (SCLC) is myelotoxic chemo-
therapy. For patients receiving systemic treatment, platinum based 
regimens are used in the adjuvant setting, in combination with radiation 
for inoperable Stage III A/B and as primary therapy for advanced stage 
patients. While multiple different regimens have been developed and 
some alternative non-platinum based regimens are also used, all of 
these regimens have been developed with neutropenia as a limiting 
toxicity, which in fact has helped deﬁne the dose schedule of many of 
these regimens. Furthermore, these chemotherapy combinations were 
developed in younger, healthier patients, but are now applied world-
wide across a population of older patients with more co-morbid disease 
and therefore, more at risk for complications of treatment. Thus, both 
neutropenia and anemia are common sequallae of treatment that impact 
the quality of life and outcomes of patients being treated. While throm-
bocytopenia can also be an issue, it is not generally limiting except in 
patients with signiﬁcant bone marrow involvement , extensive prior 
chemotherapy and radiation and/or very advanced disease, particularly 
hepatic metastasis. While Interleukin 11 is available for treatment 
of patients with thrombocytopenia, its use has been limited. New 
thrombopoietic molecules have shown promising activity in immune 
thrombocytopenia and are just beginning to be studied as an adjunct to 
chemotherapy.
The risk of neutropenia and neutropenic complications varies sig-
niﬁcantly between patients with SCLC or NSCLC. In a prospective, 
nationwide registry in the United States, patients with SCLC receiving 
chemotherapy have nearly a 20% risk of developing febrile neutropenia 
at some point in their treatment course. At this level of risk, most pa-
tients with SCLC receiving standard platinum etoposide chemotherapy 
would be candidates for ﬁrst cycle proplylaxis with colony stimulating 
factors as established by NCCN guidelines and subsequently supported 
by the EORTC and ASCO expert panels. By contrast, patients with 
NSCLC have a substantially lower risk of developing febrile neutro-
penia with an overall rate of less than 5-10% in unselected populations 
receiving platinum based chemotherapy. The differences in risk may 
have to do with the briefer periods of neutropenia seen with taxanes 
or weekly vinorelbine or gemcitabine, used in NSCLC, compared to 
etoposide or irinotecan, more commonly used in SCLC. There are 
also overall differences between SCLC and NSCLC patients in terms 
of age, functional status, extent of disease, bone marrow involvement 
that may also be associated with poorer tolerance of myelosuppressive 
chemotherapy for the small cell population. 
SCLC was recognized as a rapidly fatal cancer and aggressive chemo-
therapy regimens were developed decades ago that led to signiﬁcant 
increase in survival, symptom improvement and quality of life beneﬁt. 
Studies of high dose chemotherapy have been largely unsuccessful in 
further improving outcomes, while the delivery of dose dense chemo-
therapy with the use of colony stimulating factors has provided modest 
improvement. However, reducing the dose of chemotherapy clearly led 
to reduced beneﬁt. With the availability of myeloid growth factors, neu-
tropenic complications can be minimized for the majority of patients 
and standard dose intensity maintained in the extensive stage patients. 
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For patients with potentially curable limited stage SCLC, concurrent 
administration of myeloid growth factors with chemotherapy and radia-
tion has led to paradoxical worsening of cytopenias, presumably related 
to radiation damage of CSF mobilized peripheral blood stem cells. 
This remains a poorly studied area. Carefully done studies that vary the 
timing of myeloid growth factors in relationship to chemotherapy and 
radiation might be very informative. 
For NSCLC, in the era of platinum based treatment in patients with 
advanced disease, a survival beneﬁt has clearly been shown, but it is 
quite modest in nature. Therefore, with the perceived lower beneﬁt of 
chemotherapy in NSCLC, there has also been an intent to minimize 
toxicity, often by altering dose and schedule of chemotherapy. In the 
case of paclitaxel, switching from prolonged infusions to short infu-
sions reduced the duration of neutropenia. Other regimens have moved 
to weekly administration rather than every three weeks which also 
allow one to titrate or eliminate the subsequent doses that may worsen 
myelosuppression. Interestingly, even in advanced stage NSCLC, the 
development of neutropenia is associated with a longer survival com-
pared to patients who do not have neutropenia. While neutropenia may 
be telling us about pharmacogenomics, it suggests that dose may be an 
important variable, even on advanced stage lung cancer patients, and 
this may have implications for chemotherapy in earlier stage disease. 
Now that adjuvant chemotherapy has become a standard part of 
practice in Stage IB, III NSCLC, it is important to fully understand the 
relationship of dose and schedule to outcome. In this curative setting, it 
is also important to understand which patients are most at risk for neu-
tropenia and who might beneﬁt from early intervention strategies. The 
ANC Study Group has developed a risk model for factors associated 
with the likelihood of neutropenic complications, febrile neutropenia 
and dose reduction. These models now need to be applied prospectively 
in selected populations. The need for such a prospective risk model is 
also important for patients with more advanced NSCLC. Because the 
individual risk is low, ﬁrst cycle prophylaxis is not commonly applied. 
However, because a large number of patients treated with NSCLC 
have co-morbidities, the number of NSCLC patients hospitalized with 
febrile neutropenia is substantial. Furthermore, the clinical course for 
patients with febrile neutropenia in the setting of lung cancer is more 
similar to patients with hematologic malignancies than with other solid 
tumors such as breast cancer. Although the reasons for this are not fully 
explored, advanced age and co-morbidity may account for the higher 
mortality rate from febrile neutropenia, as well as need for prolonged 
hospitalization in many patients. Therefore, identifying patients at risk 
not only for febrile neutropenia, but for prolonged complications is 
another important area for study. 
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Staging of cancers has traditionally been based on the requirement to 
accurately define patients with localised disease that can be treated 
with surgical resection with curative intent. For certain malignancies, 
this involves defining involvement of regional lymph nodes that can 
be resected in continuity with the primary or separately. The finding 
of metastatic disease beyond regional nodes alters the treatment to 
primarily systemic and in most solid tumours from cure to palliation.
Small cell lung cancer challenges this paradigm. Prior to the introduc-
tion of systemic therapy, there was no realistic curative approach for 
localised disease, with case series reporting median survivals of less 
than 2 months with surgery and/or radiation. The introduction of multi-
agent systemic chemotherapy substantially extended median survival 
both in patients with metastatic disease and in those with apparent 
localised disease. However, the ﬁnding that radiation therapy could sig-
niﬁcantly enhance the outcome of systemic chemotherapy, particularly 
the longer term survival chances, results in the primary goal of SCLC 
‘staging’ being the determination on whether thoracic radiation therapy 
is appropriate or not. Thus ‘limited’ SCLC is not a staging that directly 
reﬂects T and N stage, but a deﬁnition based on the ability to treat a 
patient with radiation therapy ﬁelds that encompass the tumour volume. 
Determining the extent of intrathoracic disease is only important when 
it removes the possibility of ‘encompassing’ by radiation ﬁelds, for 
example ﬁnding a malignant pleural effusion. Minor nuances, such as 
whether contralateral mediastinal nodes are ‘limited’ or ‘extensive’, are 
not relevant.
The search for ‘extensive’ SCLC has progressively followed advances 
in diagnostic imaging. Since the 1970s, CT scanning, nuclear bone 
scans, MRI scanning, and F18-FDG-PET scanning have been applied 
to identify sites of disease in SCLC patients and all have reported the 
ability to detect disease otherwise missed and so ‘upstage’ patients to 
extensive disease. Integrated PET/CT scanning has not been reported in 
detail in SCLC but is likely to improve the accuracy of PET scanning 
in SCLC also. The replacement of multiple staging investigations by a 
single investigation is likely to reduce costs and patient inconvenience 
and PET/CT may provide this particularly if adequate images of the 
brain can be obtained. PET scanning can also potentially aid radiation 
therapy planning in SCLC, as in NSCLC, by deﬁning central tumour 
mass versus collapsed lung, and detecting involvement of anatomically 
normal lymph nodes.
While routine bone marrow biopsies are no longer part of SCLC 
staging, studies that have examined bone marrow by more reﬁned 
techniques than routine H & E staining have reported much higher 
detection of malignant cells than is otherwise the case. In the era when 
high dose therapy and stem cell transplant were being investigated for 
SCLC treatment, a high incidence of detecting circulating tumor cells 
in peripheral blood was reported. It is therefore likely that there is no 
such thing as truly ‘limited’ SCLC, but all patients have ‘extensive dis-
ease’ that could be detected by more reﬁned diagnostic imaging and/or 
molecular pathology.
Therefore the goal of staging a patient with SCLC is not deﬁning 
anatomical disease parameters but deciding whether a sufﬁciently large 
percentage of the burden of tumour cells are anatomically situated 
where delivery of a sufﬁcient dose of radiation therapy to potentially 
eradicate chemotherapy-resistant clones is possible. This is dependent 
not only on staging but to some extent on the judgement of the radia-
tion oncologist and will alter with advances in techniques of radiation 
delivery and planning. Use of a TNM-type staging paradigm in SCLC 
does not reﬂect either disease biology or direct treatment, so is not ap-
propriate.
